Visral20 mg

Visral 20 mg is a potent antispasmodic and anticholinergic drug primarily used to relieve smooth muscle spasms and associated pain across several body systems, including the intestine, biliary tract, urinary bladder, and uterus.

Approved Indications

• Gastrointestinal disorders: Symptomatic relief of abdominal pain, cramping, and spasm caused by functional disorders of the digestive tract, including irritable bowel syndrome (IBS), intestinal colic, and gastroenteritis-related spasm.
• Biliary system disorders: Treatment of biliary colic and spasmodic pain associated with gallbladder and bile duct conditions, including cholelithiasis and cholecystitis.
• Urological disorders: Management of spasm and pain in conditions such as urinary colic, renal colic, and bladder spasm caused by urological diseases or catheterization.
• Gynaecological disorders: Relief of uterine spasm and dysmenorrhoea (painful menstruation) and spasmodic pain in the female reproductive tract.

In clinical practice, Visral 20 mg is prescribed for the short-term symptomatic relief of visceral pain rather than as a curative treatment. It does not address the underlying cause of the condition. Always use this medicine under the supervision of a registered physician.

Visral 20 mg exerts its therapeutic effects through a multi-target mechanism of action that reduces smooth muscle (visceral) contractility and relieves spasm-induced pain.

Mechanism of Action

• Competitive anticholinergic activity: Visral 20 mg acts as a competitive antagonist at muscarinic acetylcholine receptors on smooth muscle cells. By blocking the action of acetylcholine, it prevents receptor-mediated smooth muscle contraction in the gut, biliary tract, bladder, and uterus.
• Antihistaminic activity: It also competitively antagonises histamine at receptor sites, further contributing to its antispasmodic and analgesic effects on visceral smooth muscle.
• Calcium membrane stabilisation: Visral 20 mg strengthens the bond of calcium with membrane phospholipids and membrane proteins. This stabilisation inhibits the intracellular mobilisation of calcium required for smooth muscle contraction, thereby blocking the activation of contractile proteins within visceral cells.

Therapeutic Result

Through these combined mechanisms, Visral 20 mg effectively inhibits visceral smooth muscle spasm and reduces the associated pain, providing rapid symptomatic relief in acute and chronic spasmodic conditions. Its quaternary ammonium structure limits its passage across the blood-brain barrier, resulting in fewer central nervous system side effects compared to tertiary anticholinergic agents.

Although specific drug-drug interaction data for Visral 20 mg is limited in published literature, its anticholinergic and antihistaminic properties create a risk of interactions with several pharmacological agents. Patients should always inform their physician of all medications they are currently taking before starting Visral 20 mg.

Potential Interactions to be Aware Of

• Other anticholinergic drugs: Concurrent use with other anticholinergic medications (e.g., atropine, hyoscine, tricyclic antidepressants, certain antihistamines) may lead to additive anticholinergic effects, including dry mouth, urinary retention, blurred vision, constipation, and tachycardia.
• Antihypertensive agents: The risk of hypotension may be enhanced when Visral 20 mg is given alongside antihypertensive medications, particularly via the intravenous route.
• Central nervous system depressants: Although Visral 20 mg has limited CNS penetration due to its quaternary ammonium structure, caution is advised when used alongside sedatives, tranquillisers, or alcohol.
• Prokinetic agents: The antispasmodic effect of Visral 20 mg may oppose the prokinetic action of drugs like metoclopramide or domperidone, reducing their therapeutic effectiveness.

Do not combine Visral 20 mg with any other medication without prior consultation with a registered physician to avoid possible adverse drug interactions.

Visral 20 mg is generally well tolerated when used at recommended doses. However, like all anticholinergic drugs, it may cause side effects in some individuals. Patients should be aware of the following:

Cardiovascular

• Hypotension (low blood pressure): A drop in blood pressure may occur, particularly with intravenous administration. This can cause dizziness, lightheadedness, or fainting, especially when standing up quickly (orthostatic hypotension).
• Tachycardia (fast heart rate): An increased heart rate may be observed as a result of the drug's anticholinergic activity on cardiac muscarinic receptors.

Anticholinergic Effects (Class-related)

• Dry mouth
• Blurred vision or difficulty focusing (due to cycloplegia)
• Urinary hesitancy or retention (especially in men with prostate enlargement)
• Constipation
• Reduced sweating (anhidrosis), which may predispose to overheating in hot environments

Visual Disturbances

• Visual disturbances have been noted and may impair the ability to drive or operate machinery safely. Patients should exercise caution during activities requiring visual acuity and alertness.

If you experience chest pain, difficulty breathing, severe dizziness, or sudden vision changes, discontinue use and seek immediate medical attention.

Pregnancy

Animal reproductive studies with Visral 20 mg have not demonstrated any teratogenic effects, and no congenital deformities have been reported with normal therapeutic use in humans. However, adequate and well-controlled studies in pregnant women are lacking. Because the safety of Visral 20 mg during human pregnancy has not been fully established, it should be used during pregnancy only when clearly necessary and under direct medical supervision. The potential benefit to the mother must always be weighed carefully against any possible risk to the foetus.

Lactation

It is not known whether Visral 20 mg is excreted in human breast milk. In the absence of sufficient clinical data on lactation safety, prudence should be the rule. Nursing mothers should consult their physician before using this medication. If use is considered essential, breastfeeding may need to be temporarily discontinued during the course of treatment.

The following precautions should be observed during treatment with Visral 20 mg to minimise the risk of adverse events:

• Prostatic disorders: Exercise caution when prescribing Visral 20 mg to male patients with a history of prostate enlargement or other prostatic disorders, due to the risk of precipitating urinary retention from anticholinergic activity on the bladder.
• Chronic bronchitis and respiratory conditions: Patients with chronic obstructive pulmonary disease (COPD) or chronic bronchitis should be monitored carefully, as reduced mucous secretion from anticholinergic effects may worsen mucus clearance.
• Coronary insufficiency: Caution is warranted in patients with ischaemic heart disease or coronary insufficiency, particularly because tachycardia induced by the drug can increase myocardial oxygen demand.
• Ambient hyperthermia: Due to reduced sweating caused by anticholinergic activity, patients are at increased risk of heat stroke in hot environments. Adequate hydration and avoidance of excessive heat are advised during treatment.
• Renal impairment: Patients with reduced kidney function may have impaired drug clearance, necessitating dose adjustment and careful monitoring.
• Hepatic impairment: Caution is required in patients with liver disease, as hepatic metabolism of the drug may be affected.
• Driving and machinery: Visual disturbances associated with Visral 20 mg may impair the ability to drive safely or operate machinery. Patients should be advised not to perform such activities until they know how the drug affects them.
• Elderly patients: Older adults may be more sensitive to anticholinergic side effects, including confusion, urinary retention, and falls due to hypotension. Close monitoring is recommended.

Specific data on the clinical presentation and management of Visral 20 mg overdose in humans is currently limited in the published literature. However, based on its pharmacological profile as an anticholinergic agent, an overdose may be expected to cause an exaggeration of its known anticholinergic effects, potentially including:

• Severe dry mouth, flushing, and fever
• Marked tachycardia and palpitations
• Urinary retention
• Blurred vision and photophobia
• Agitation, confusion, or disorientation
• Significant hypotension

In the event of suspected overdose, the patient should receive immediate supportive medical care. Treatment is primarily symptomatic and supportive. Activated charcoal may be considered for recent oral ingestion if the patient is alert and the airway is protected. Do not attempt to self-treat an overdose. Contact a poison control centre or go to the nearest emergency department immediately.

• Store in a dry place: Keep away from moisture and humidity. Do not store in bathrooms or near the kitchen sink.
• Protect from light: Store in the original packaging or an opaque container, away from direct sunlight and artificial light sources.
• Protect from heat: Keep at room temperature (below 30°C). Do not store in locations subject to extreme heat, such as inside a car.
• Keep out of reach of children: Store all medications, including Visral 20 mg tablets, syrup, injections, and suppositories, in a secure location inaccessible to children.
• Do not use after expiry: Check the expiry date printed on the packaging before use. Discard expired medication safely.
• Injection ampoules: Opened ampoules must be used immediately and any unused portion discarded. Do not store partially used ampoules.

Paediatric Use

The safety and effectiveness of Visral 20 mg in paediatric patients have not been formally established through controlled clinical trials. Despite this, weight-based dosing guidelines (3 ml/kg or 6 mg/kg per day in divided doses) are available for children, and the syrup formulation is commonly used in clinical practice for this age group. Any use in children should be under strict medical supervision, with careful attention to dosing accuracy and monitoring for adverse effects.

Geriatric Use

Available data suggest that the efficacy and safety profile of Visral 20 mg is generally maintained with increasing age. However, elderly patients may be more vulnerable to anticholinergic side effects such as urinary retention, constipation, dry mouth, confusion, and cardiovascular effects including hypotension and tachycardia. Physicians should initiate treatment at the lower end of the dosing range in older patients and monitor closely for adverse events.

Renal & Hepatic Impairment

Patients with significant renal or hepatic impairment may experience altered pharmacokinetics of the drug. Clinical caution and potential dose adjustment are advised, as discussed under Precautions & Warnings.